Website
Neuren Pharmaceuticals LimitedTelephone
61.3.9092.0480
Address
Suite 201 697 Burke Road Camberwell, Victoria (VIC) 3124
Description
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 12.02 - 25.95
Trade Value (12mth)
AU$2,373,444.00
1 week
6.02%
1 month
8.51%
YTD
-46.05%
1 year
-16.88%
All time high
25.95
EPS 3 yr Growth
-1539.10%
EBITDA Margin
85.90%
Operating Cashflow
$185m
Free Cash Flow Return
149.90%
ROIC
127.30%
Interest Coverage
N/A
Quick Ratio
5.80
Shares on Issue (Fully Dilluted)
131m
HALO Sector
Healthcare
Next Company Report Date
04-Mar-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
3.20
Date | Announcements |
---|---|
04 December 24 |
Update - Notification of buy-back - NEU
×
Update - Notification of buy-back - NEU |
03 December 24 |
Update - Notification of buy-back - NEU
×
Update - Notification of buy-back - NEU |
15 November 24 |
Investor presentation, 15 November 2024
×
Investor presentation, 15 November 2024 |
14 November 24 |
Neuren announces A$50m on-market share buy-back program
×
Neuren announces A$50m on-market share buy-back program |
14 November 24 |
Notification of buy-back - NEU
×
Notification of buy-back - NEU |
07 November 24 |
Pause in Trading
×
Pause in Trading |
07 November 24 |
Q3 2024 update
×
Q3 2024 update |
06 November 24 |
PRV sold for US$150m - Neuren to receive one third
×
PRV sold for US$150m - Neuren to receive one third |
01 November 24 |
Updated Share Trading Policy
×
Updated Share Trading Policy |
28 October 24 |
Notification of cessation of securities - NEU
×
Notification of cessation of securities - NEU |
17 October 24 |
DAYBUE receives marketing authorization in Canada
×
DAYBUE receives marketing authorization in Canada |
07 October 24 |
NEU continues PMS P3 preparations after positive FDA meeting
×
NEU continues PMS P3 preparations after positive FDA meeting |
27 August 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
27 August 24 |
H1 2024 financial results
×
H1 2024 financial results |
19 August 24 |
Investor roadshow presentation, 19 August 2024
×
Investor roadshow presentation, 19 August 2024 |
16 August 24 |
Change of Director's Interest Notice - J Basile
×
Change of Director's Interest Notice - J Basile |
09 August 24 |
Phase 2 trial shows significant improvements in Angelman
×
Phase 2 trial shows significant improvements in Angelman |
09 August 24 |
NNZ-2591 Angelman top-line results presentation
×
NNZ-2591 Angelman top-line results presentation |
07 August 24 |
Q2 2024 update
×
Q2 2024 update |
07 August 24 |
Pause in Trading
×
Pause in Trading |
07 August 24 |
Trading Halt
×
Trading Halt |
25 July 24 |
Neuren to participate in upcoming US investor conferences
×
Neuren to participate in upcoming US investor conferences |
19 July 24 |
Neuren receives Rare Pediatric Disease Designation from FDA
×
Neuren receives Rare Pediatric Disease Designation from FDA |
19 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 July 24 |
Final Director's Interest Notice - T Scott
×
Final Director's Interest Notice - T Scott |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.